|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/137 | (2006.01) |
| A61P 37/06 | (2006.01) | ||
| A61K 31/397 | (2006.01) |
| (11) | Number of the document | 2959894 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15177166.4 |
| Date of filing the European patent application | 2007-06-25 | |
| (97) | Date of publication of the European application | 2015-12-30 |
| (45) | Date of publication and mention of the grant of the patent | 2022-10-12 |
| (46) | Date of publication of the claims translation | 2022-11-10 |
| (30) | Number | Date | Country code |
| 0612721 | 2006-06-27 | GB |
| (72) |
Hiestand, Peter C. , CH
Schnell, Christian , FR
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | S1P receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui |
| S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS |
| Payment date | Validity (years) | Amount | |
| 2025-05-22 | 19 | 347.00 EUR |
| 2026-06-25 |